Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on ATYR stock, giving a Buy rating on May 19.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Faisal Khurshid has given his Buy rating due to a combination of factors related to aTyr Pharma’s ongoing clinical trial for efzofitimod in pulmonary sarcoidosis. The Phase 3 EFZO-FIT trial is anticipated to yield significant data by the third quarter of 2025, which is a pivotal event for the stock. The trial’s baseline characteristics align with expectations for a global study, suggesting that the enrolled patient population is appropriate for this indication.
Khurshid believes that the EFZO-FIT trial has a strong likelihood of success, particularly in achieving its primary endpoint of steroid reduction. This confidence is bolstered by the trial’s favorable design, the execution quality, and supportive data from earlier Phase 1/2 trials. Additionally, the trial’s lower baseline steroid dose and dyspnea scores are seen as consistent with global study norms, potentially enriching the trial’s chances of success by targeting a population less likely to have been over-treated with steroids.
Khurshid covers the Healthcare sector, focusing on stocks such as Trevi Therapeutics, aTyr Pharma, and Kymera Therapeutics. According to TipRanks, Khurshid has an average return of 24.3% and a 45.57% success rate on recommended stocks.
In another report released on May 19, H.C. Wainwright also reiterated a Buy rating on the stock with a $35.00 price target.